PHOENIX ― Gastrointestinal cancers are some of the most commonly diagnosed cancers, and they continue to be associated with poor survival outcomes. The drug adagrasib specifically targets the KRASG12C gene mutation that is common in gastrointestinal cancers and inhibits gastrointestinal function.
Trending
- Meet the gastroenterologists of the 10 top hospitals for GI (Becker’s GI & Endoscopy)
- Acute gastroenteritis linked to increased odds for postinfection IBS, functional dyspepsia (Healio)
- Private equity-backed providers represent less than 4% of US market: PitchBook (Healthcare Dive)
- In Memoriam: Ikuo Hirano, MD, AGAF (AGA)
- Exact Sciences Awards Grants to 28 Organizations Focused on Increasing Colorectal Cancer Screening (Business Wire)
- Video: Early Detection and Innovative Solutions for Colorectal Cancer with Michael Sapienza (Target Cancer | Youtube)
- Risk Stratification May Work Well for FIT-Based CRC Screening in Elderly (MDedge)
- AI In Medicine: 3 Future Scenarios From Utopia To Dystopia (The Medical Futurist)